Immune system: A possible nexus between cannabinoids and psychosis

Brain, Behavior, and Immunity

Volumn 40, Issue , 2014, Pages 269-282

  Suárez Pinilla, Paula ^a,b,c   López Gil, José ^a   Crespo Facorro, Benedicto ^a,b,c  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c IDIVAL   (Spain)

Author keywords

Cytokines; Endocannabinoid system; First episode psychosis; Immunology; Infection; Microglia; Schizophrenia

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; CYTOKINE; ENDOCANNABINOID; LIGAND; CANNABINOID RECEPTOR AFFECTING AGENT;

B LYMPHOCYTE; BRAIN CELL; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; DRUG EXPOSURE; EMBASE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INFORMATION RETRIEVAL; MEDLINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TUMOR CELL; ANIMAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE; METABOLISM; PHYSIOLOGY; PSYCHOTIC DISORDERS; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; CANNABINOID RECEPTOR MODULATORS; CANNABINOIDS; CYTOKINES; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; LEUKOCYTES; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; T-LYMPHOCYTES;

EID: 84904101669     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.01.018     Document Type: Review

References (193)

1. Adhikary S., Kocieda V.P., Yen J.H., Tuma R.F., Ganea D. Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood 2012, 120(18):3741-3749.
2. Agudelo M., Newton C., Widen R., Sherwood T., Nong L., Friedman H., et al. Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. J. Neuroimmune Pharmacol. 2008, 3(1):35-42.
3. Altinsoy A., Dilekoz E., Kul O., Ilhan S.O., Tunccan O.G., Seven I., et al. A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits. J. Ocul. Pharmacol. Ther. 2011, 27(6):545-552.
4. Alvaro-Bartolome M., Esteban S., Garcia-Gutierrez M.S., Manzanares J., Valverde O., Garcia-Sevilla J.A. Regulation of Fas receptor/Fas-associated protein with death domain apoptotic complex and associated signalling systems by cannabinoid receptors in the mouse brain. Br. J. Pharmacol. 2010, 160(3):643-656.
5. Amenta P.S., Jallo J.I., Tuma R.F., Elliott M.B. A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J. Neurosci. Res. 2012, 90(12):2293-2305.
6. Arevalo-Martin A., Molina-Holgado E., Guaza C. A CB(1)/CB(2) receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin. Neuropharmacology 2012, 63(3):385-393.
7. Auclair N., Otani S., Soubrie P., Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J. Neurophysiol. 2000, 83(6):3287-3293.
8. Avraham Y., Amer J., Doron S., Abu-Tair L., Mahamid M., Khatib A., et al. The direct profibrotic and indirect immune antifibrotic balance of blocking the cannabinoid 2 receptor. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302(12):G1364-G1372.
9. Ayalew M., Le-Niculescu H., Levey D.F., Jain N., Changala B., Patel S.D., et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol. Psychiatry 2012, 17(9):887-905.
10. Balenga N.A., Aflaki E., Kargl J., Platzer W., Schroder R., Blattermann S., et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 2011, 21(10):1452-1469.
11. Basu S., Ray A., Dittel B.N. Cannabinoid receptor 2 (CB2) plays a role in the generation of germinal center and memory B cells, but not in the production of antigen-specific IgG and IgM, in response to T-dependent antigens. PLoS ONE 2013, 8(6):e67587.
12. Bento A.F., Marcon R., Dutra R.C., Claudino R.F., Cola M., Leite D.F., et al. Beta-caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARgamma pathway. Am. J. Pathol. 2011, 178(3):1153-1166.
13. Bernstein H.G., Steiner J., Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev. Neurother. 2009, 9(7):1059-1071.
14. Bioque M., Garcia-Bueno B., Macdowell K.S., Meseguer A., Saiz P.A., Parellada M., et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology 2013, 38(13):2568-2577.
15. Borner C., Smida M., Hollt V., Schraven B., Kraus J. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J. Biol. Chem. 2009, 284(51):35450-35460.
16. Borovcanin M., Jovanovic I., Radosavljevic G., Djukic Dejanovic S., Bankovic D., Arsenijevic N., et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J. Psychiatr. Res. 2012, 46(11):1421-1426.
17. Braun A., Engel T., Aguilar-Pimentel J.A., Zimmer A., Jakob T., Behrendt H., et al. Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors. Immunobiology 2011, 216(4):466-476.
18. Buchweitz J.P., Karmaus P.W., Harkema J.R., Williams K.J., Kaminski N.E. Modulation of airway responses to influenza A/PR/8/34 by Delta9-tetrahydrocannabinol in C57BL/6 mice. J. Pharmacol. Exp. Ther. 2007, 323(2):675-683.
19. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 2000, 396(2-3):141-149.
20. Buckley N.E., Burbridge D., Buranapramest M., Ferguson T., Paau R.Y. Experimental methods to study the role of the peripheral cannabinoid receptor in immune function. Methods Mol. Med. 2006, 123:19-40.
21. Busse S., Busse M., Schiltz K., Bielau H., Gos T., Brisch R., et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations?. Brain Behav. Immun. 2012, 26(8):1273-1279.
22. Cabral G.A., Griffin-Thomas L. Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr. Metab. Immune Disord. Drug Targets 2008, 8(3):159-172.
23. Cabral G.A., Marciano-Cabral F. Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J. Neuroimmunol. 2004, 147(1-2):127-130.
24. Cabral G.A., Staab A. Effects on the immune system. Handb. Exp. Pharmacol. 2005, 168:385-423.
25. Cannon T.D., Kaprio J., Lonnqvist J., Huttunen M., Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch. Gen. Psychiatry 1998, 55(1):67-74.
26. Caraceni P., Pertosa A.M., Giannone F., Domenicali M., Grattagliano I., Principe A., et al. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia. Gut 2009, 58(8):1135-1143.
27. Catts V.S., Catts S.V., McGrath J.J., Feron F., McLean D., Coulson E.J., et al. Apoptosis and schizophrenia: a pilot study based on dermal fibroblast cell lines. Schizophr. Res. 2006, 84(1):20-28.
28. Cazzullo C.L., Scarone S., Grassi B., Vismara C., Trabattoni D., Clerici M. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22(6):947-957.
29. Cencioni M.T., Chiurchiu V., Catanzaro G., Borsellino G., Bernardi G., Battistini L., et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 2010, 5(1):e8688.
30. Centonze D., Battistini L., Maccarrone M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr. Pharm. Des. 2008, 14(23):2370-2382.
31. Chen M.L., Tsai T.C., Wang L.K., Lin Y.Y., Tsai Y.M., Lee M.C., et al. Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-alpha-directed cell apoptosis in neutrophils. Int. Immunopharmacol. 2012, 12(1):197-204.
32. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 2006, 29:37-76.
33. Chew L.J., Fusar-Poli P., Schmitz T. Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. Dev. Neurosci. 2013, 35(2-3):102-129.
34. Chicca A., Raduner S., Pellati F., Strompen T., Altmann K.H., Schoop R., et al. Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int. Immunopharmacol. 2009, 9(7-8):850-858.
35. Childers S.R., Pacheco M.A., Bennett B.A., Edwards T.A., Hampson R.E., Mu J., et al. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem. Soc. Symp. 1993, 59:27-50.
36. Coopman K., Smith L.D., Wright K.L., Ward S.G. Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int. Immunopharmacol. 2007, 7(3):360-371.
37. Correa F., Docagne F., Mestre L., Clemente D., Hernangomez M., Loria F., et al. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem. Pharmacol. 2009, 77(1):86-100.
38. Correa F., Hernangomez M., Mestre L., Loria F., Spagnolo A., Docagne F., et al. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 2010, 58(2):135-147.
39. Crespo-Facorro B., Carrasco-Marin E., Perez-Iglesias R., Pelayo-Teran J.M., Fernandez-Prieto L., Leyva-Cobian F., et al. Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res. 2008, 158(2):206-216.
40. Croxford J.L., Wang K., Miller S.D., Engman D.M., Tyler K.M. Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression. Cell. Microbiol. 2005, 7(11):1592-1602.
41. Cutando L., Busquets-Garcia A., Puighermanal E., Gomis-Gonzalez M., Delgado-Garcia J.M., Gruart A., et al. Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. J. Clin. Invest. 2013, 123(7):2816-2831.
42. Dalton V.S., Verdurand M., Walker A., Hodgson D.M., Zavitsanou K. Synergistic effect between maternal infection and adolescent cannabinoid exposure on serotonin 5HT1A receptor binding in the hippocampus: testing the "Two Hit" hypothesis for the development of schizophrenia. ISRN Psychiatr. 2012, 2012:451865.
43. De Filippis D., Esposito G., Cirillo C., Cipriano M., De Winter B.Y., Scuderi C., et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS ONE 2011, 6(12):e28159.
44. DeLisi L.E. The significance of age of onset for schizophrenia. Schizophr. Bull. 1992, 18(2):209-215.
45. Deusch E., Kraft B., Nahlik G., Weigl L., Hohenegger M., Kress H.G. No evidence for direct modulatory effects of delta 9-tetrahydrocannabinol on human polymorphonuclear leukocytes. J. Neuroimmunol. 2003, 141(1-2):99-103.
46. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258(5090):1946-1949.
47. Do Y., McKallip R.J., Nagarkatti M., Nagarkatti P.S. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol. 2004, 173(4):2373-2382.
48. Downer E.J., Clifford E., Gran B., Nel H.J., Fallon P.G., Moynagh P.N. Identification of the synthetic cannabinoid R(+)WIN55,212-2 as a novel regulator of IFN regulatory factor 3 activation and IFN-beta expression: relevance to therapeutic effects in models of multiple sclerosis. J. Biol. Chem. 2011, 286(12):10316-10328.
49. Dutra R.C., Simao da Silva K.A., Bento A.F., Marcon R., Paszcuk A.F., Meotti F.C., et al. Euphol, a tetracyclic triterpene produces antinociceptive effects in inflammatory and neuropathic pain: the involvement of cannabinoid system. Neuropharmacology 2012, 63(4):593-605.
50. Eaton W.W., Pedersen M.G., Nielsen P.R., Mortensen P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010, 12(6):638-646.
51. Eggan S.M., Hashimoto T., Lewis D.A. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 2008, 65(7):772-784.
52. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflamm. 2005, 2:29.
53. Eisenstein T.K., Meissler J.J., Wilson Q., Gaughan J.P., Adler M.W. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J. Neuroimmunol. 2007, 189(1-2):17-22.
54. El-Gohary M., Eid M.A. Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum. Exp. Toxicol. 2004, 23(3):149-156.
55. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt P.M., Wolf S., et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006, 49(1):67-79.
56. Esposito E., Paterniti I., Mazzon E., Genovese T., Di Paola R., Galuppo M., et al. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav. Immun. 2011, 25(6):1099-1112.
57. Faubert Kaplan BL B.L., Kaminski N.E. Cannabinoids inhibit the activation of ERK MAPK in PMA/Io-stimulated mouse splenocytes. Int. Immunopharmacol. 2003, 3(10-11):1503-1510.
58. Fernandez-Espejo E., Viveros M.P., Nunez L., Ellenbroek B.A., Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 2009, 206(4):531-549.
59. Finlay B.L., Darlington R.B. Linked regularities in the development and evolution of mammalian brains. Science 1995, 268(5217):1578-1584.
60. Franklin A., Stella N. Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur. J. Pharmacol. 2003, 474(2-3):195-198.
61. Franklin A., Parmentier-Batteur S., Walter L., Greenberg D.A., Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci. 2003, 23(21):7767-7775.
62. Fride E. The endocannabinoid-CB receptor system: importance for development and in pediatric disease. Neuro. Endocrinol. Lett. 2004, 25(1-2):24-30.
63. Gaffal E., Cron M., Glodde N., Tuting T. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy 2013, 68(8):994-1000.
64. Ganguli R., Brar J.S., Chengappa K.R., DeLeo M., Yang Z.W., Shurin G., et al. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch. Gen. Psychiatry 1995, 52(8):668-672.
65. Garcia-Bueno B., Bioque M., Mac-Dowell K.S., Barcones M.F., Martinez-Cengotitabengoa M., Pina-Camacho L., et al. Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr. Bull. 2013, http://dx.doi.org/10.1093/schbul/sbt001.
66. Genius J., Benninghoff J., Reuter N., Braun I., Giegling I., Hartmann A., et al. Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis. Methods 2012, 56(4):519-527.
67. Ghosh S., Preet A., Groopman J.E., Ganju R.K. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol. Immunol. 2006, 43(14):2169-2179.
68. Gokoh M., Kishimoto S., Oka S., Sugiura T. 2-Arachidonoylglycerol enhances the phagocytosis of opsonized zymosan by HL-60 cells differentiated into macrophage-like cells. Biol. Pharm. Bull. 2007, 30(7):1199-1205.
69. Gongora C., Hose S., O'Brien T.P., Sinha D. Downregulation of class II transactivator (CIITA) expression by synthetic cannabinoid CP55,940. Immunol. Lett. 2004, 91(1):11-16.
70. Gorantla S., Makarov E., Roy D., Finke-Dwyer J., Murrin L.C., Gendelman H.E., et al. Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS. J. Neuroimmune Pharmacol. 2010, 5(3):456-468.
71. Graham E.S., Ashton J.C., Glass M. Cannabinoid receptors: a brief history and "what's hot". Front. Biosci. (Landmark Ed.) 2009, 14:944-957.
72. Harvey B.S., Nicotra L.L., Vu M., Smid S.D. Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability. Cytokine 2013, 63(2):209-217.
73. Hegde V.L., Hegde S., Cravatt B.F., Hofseth L.J., Nagarkatti M., Nagarkatti P.S. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol. Pharmacol. 2008, 74(1):20-33.
74. Hegde V.L., Nagarkatti M., Nagarkatti P.S. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur. J. Immunol. 2010, 40(12):3358-3371.
75. Hegde V.L., Nagarkatti P.S., Nagarkatti M. Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS ONE 2011, 6(4):e18281.
76. Hickie I.B., Banati R., Stewart C.H., Lloyd A.R. Are common childhood or adolescent infections risk factors for schizophrenia and other psychotic disorders?. Med. J. Aust. 2009, 190(4 Suppl):S17-S21.
77. Huffman J.W. CB2 receptor ligands. Mini Rev. Med. Chem. 2005, 5(7):641-649.
78. Ishiguro H., Horiuchi Y., Ishikawa M., Koga M., Imai K., Suzuki Y., et al. Brain cannabinoid CB2 receptor in schizophrenia. Biol. Psychiatry 2010, 67(10):974-982.
79. Jan T.R., Su S.T., Wu H.Y., Liao M.H. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. Int. Immunopharmacol. 2007, 7(6):773-780.
80. Joseph J., Niggemann B., Zaenker K.S., Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol. Immunother. 2004, 53(8):723-728.
81. Kaplan B.L., Springs A.E., Kaminski N.E. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem. Pharmacol. 2008, 76(6):726-737.
82. Karmaus P.W., Chen W., Crawford R.B., Harkema J.R., Kaplan B.L., Kaminski N.E. Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection. J. Leukoc. Biol. 2011, 90(5):983-995.
83. Karmaus P.W., Chen W., Crawford R., Kaplan B.L., Kaminski N.E. Delta9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2. Toxicol. Sci. 2013, 131(2):419-433.
84. Kaufmann I., Schelling G., Eisner C., Richter H.P., Krauseneck T., Vogeser M., et al. Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 2008, 33(5):676-685.
85. Kim Y.K., Myint A.M., Lee B.H., Han C.S., Lee H.J., Kim D.J., et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(7):1129-1134.
86. Kinney D.K., Hintz K., Shearer E.M., Barch D.H., Riffin C., Whitley K., et al. A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction. Med. Hypotheses 2010, 74(3):555-563.
87. Kirkpatrick B., Miller B.J. Inflammation and schizophrenia. Schizophr. Bull. 2013, 39(6):1174-1179.
88. Kishimoto S., Kobayashi Y., Oka S., Gokoh M., Waku K., Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J. Biochem. 2004, 135(4):517-524.
89. Knight J., Knight A., Ungvari G. Can autoimmune mechanisms account for the genetic predisposition to schizophrenia?. Br. J. Psychiatry 1992, 160:533-540.
90. Kraft B., Wintersberger W., Kress H.G. Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide. Life Sci. 2004, 75(8):969-977.
91. Kraus J. Expression and functions of mu-opioid receptors and cannabinoid receptors type 1 in T lymphocytes. Ann. N. Y. Acad. Sci. 2012, 1261:1-6.
92. Kringlen E. Twin studies in schizophrenia with special emphasis on concordance figures. Am. J. Med. Genet. 2000, 97(1):4-11.
93. Krishnan G., Chatterjee N. Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation. Glia 2012, 60(11):1629-1645.
94. Kronfol Z., Remick D.G. Cytokines and the brain: implications for clinical psychiatry. Am. J. Psychiatry 2000, 157(5):683-694.
95. Leweke F.M., Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict. Biol. 2008, 13(2):264-275.
96. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr. Res. 2007, 94(1-3):29-36.
97. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2012, 2:e94.
98. Lombard C., Nagarkatti M., Nagarkatti P.S. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk. Res. 2005, 29(8):915-922.
99. Lombard C., Hegde V.L., Nagarkatti M., Nagarkatti P.S. Perinatal exposure to Delta9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens. J. Pharmacol. Exp. Ther. 2011, 339(2):607-617.
100. Lou Z.Y., Chen C., He Q., Zhao C.B., Xiao B.G. Targeting CB(2) receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis. Mol. Immunol. 2011, 49(3):453-461.
101. Lou Z.Y., Zhao C.B., Xiao B.G. Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. J. Neurosci. Res. 2012, 90(1):84-95.
102. Lourbopoulos A., Grigoriadis N., Lagoudaki R., Touloumi O., Polyzoidou E., Mavromatis I., et al. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res. 2011, 16(1390):126-141.
103. Lu T.S., Avraham H.K., Seng S., Tachado S.D., Koziel H., Makriyannis A., et al. Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J. Immunol. 2008, 181(9):6406-6416.
104. Lu H., Kaplan B.L., Ngaotepprutaram T., Kaminski N.E. Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol. J. Leukoc. Biol. 2009, 85(2):322-329.
105. Lunn C.A., Fine J.S., Rojas-Triana A., Jackson J.V., Fan X., Kung T.T., et al. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. 2006, 316(2):780-788.
106. Maestroni G.J. The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. FASEB J. 2004, 18(15):1914-1916.
107. Malfitano A.M., Laezza C., D'Alessandro A., Procaccini C., Saccomanni G., Tuccinardi T., et al. Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis. PLoS ONE 2013, 8(5):e62511.
108. Marazzi J., Kleyer J., Paredes J.M., Gertsch J. Endocannabinoid content in fetal bovine sera - unexpected effects on mononuclear cells and osteoclastogenesis. J. Immunol. Methods 2011, 373(1-2):219-228.
109. Marquart S., Zerr P., Akhmetshina A., Palumbo K., Reich N., Tomcik M., et al. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum. 2010, 62(11):3467-3476.
110. Matheson S.L., Shepherd A.M., Laurens K.R., Carr V.J. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. Schizophr. Res. 2011, 133(1-3):133-142.
111. Mayilyan K.R., Weinberger D.R., Sim R.B. The complement system in schizophrenia. Drug News Perspect. 2008, 21(4):200-210.
112. McHugh D., Hu S.S., Rimmerman N., Juknat A., Vogel Z., Walker J.M., et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010, 11:44.
113. McKallip R.J., Nagarkatti M., Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 2005, 174(6):3281-3289.
114. McKernan D.P., Dennison U., Gaszner G., Cryan J.F., Dinan T.G. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl. Psychiatry 2011, 1:e36.
115. Mecha M., Feliu A., Inigo P.M., Mestre L., Carrillo-Salinas F.J., Guaza C. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol. Dis. 2013, 59:141-150.
116. Merighi S., Gessi S., Varani K., Simioni C., Fazzi D., Mirandola P., et al. Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide. Br. J. Pharmacol. 2012, 165(6):1773-1788.
117. Mestre L., Correa F., Arevalo-Martin A., Molina-Holgado E., Valenti M., Ortar G., et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 2005, 92(6):1327-1339.
118. Michler T., Storr M., Kramer J., Ochs S., Malo A., Reu S., et al. Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304(2):G181-G192.
119. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
120. Mittleman B.B., Castellanos F.X., Jacobsen L.K., Rapoport J.L., Swedo S.E., Shearer G.M. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J. Immunol. 1997, 159(6):2994-2999.
121. Mnich S.J., Hiebsch R.R., Huff R.M., Muthian S. Anti-inflammatory properties of CB1-receptor antagonist involves beta2 adrenoceptors. J. Pharmacol. Exp. Ther. 2010, 333(2):445-453.
122. Muller N., Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22(1):1-33.
123. Muller N., Riedel M., Ackenheil M., Schwarz M.J. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J. Biol. Psychiatry 2000, 1(4):173-179.
124. Muller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia. An integrative view. Ann. N. Y. Acad. Sci. 2000, 917:456-467.
125. Muller-Vahl K.R., Emrich H.M. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev. Neurother. 2008, 8(7):1037-1048.
126. Muppidi J.R., Arnon T.I., Bronevetsky Y., Veerapen N., Tanaka M., Besra G.S., et al. Cannabinoid receptor 2 positions and retains marginal zone B cells within the splenic marginal zone. J. Exp. Med. 2011, 208(10):1941-1948.
127. Newton C.A., Lu T., Nazian S.J., Perkins I., Friedman H., Klein T.W. The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2. J. Leukoc. Biol. 2004, 76(4):854-861.
128. Newton C.A., Chou P.J., Perkins I., Klein T.W. CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J. Neuroimmune Pharmacol. 2009, 4(1):92-102.
129. Ni X., Geller E.B., Eppihimer M.J., Eisenstein T.K., Adler M.W., Tuma R.F. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult. Scler. 2004, 10(2):158-164.
130. Nitta M., Kishimoto T., Muller N., Weiser M., Davidson M., Kane J.M., et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr. Bull. 2013, 39(6):1230-1241.
131. Olea-Herrero N., Vara D., Malagarie-Cazenave S., Diaz-Laviada I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2. Br. J. Cancer 2009, 101(6):940-950.
132. Onaivi E.S. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int. Rev. Neurobiol. 2009, 88:335-369.
133. Onaivi E.S., Ishiguro H., Gu S., Liu Q.R. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J. Psychopharmacol. 2012, 26(1):92-103.
134. Palazuelos J., Aguado T., Egia A., Mechoulam R., Guzman M., Galve-Roperh I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006, 20(13):2405-2407.
135. Palmer S.L., Khanolkar A.D., Makriyannis A. Natural and synthetic endocannabinoids and their structure-activity relationships. Curr. Pharm. Des. 2000, 6(13):1381-1397.
136. Palu A.K., Kim A.H., West B.J., Deng S., Jensen J., White L. The effects of Morinda citrifolia L. (noni) on the immune system: its molecular mechanisms of action. J. Ethnopharmacol. 2008, 115(3):502-506.
137. Pandey R., Hegde V.L., Nagarkatti M., Nagarkatti P.S. Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model. J. Pharmacol. Exp. Ther. 2011, 338(3):819-828.
138. Pathmanandavel K., Starling J., Dale R.C., Brilot F. Autoantibodies and the immune hypothesis in psychotic brain diseases: challenges and perspectives. Clin. Dev. Immunol. 2013, 2013:257184.
139. Paulsen K., Tauber S., Timm J., Goelz N., Dumrese C., Stolzing A., et al. The cannabinoid receptors agonist WIN55212-2 inhibits macrophageal differentiation and alters expression and phosphorylation of cell cycle control proteins. Cell Commun. Signal. 2011, 9:33.
140. Pellerito O., Calvaruso G., Portanova P., De Blasio A., Santulli A., Vento R., et al. The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. Mol. Pharmacol. 2010, 77(5):854-863.
141. Pertwee R.G. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci. 1999, 65(6-7):597-605.
142. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4(11):873-884.
143. Pryce G., Ahmed Z., Hankey D.J., Jackson S.J., Croxford J.L., Pocock J.M., et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126(Pt. 10):2191-2202.
144. Ramirez S.H., Hasko J., Skuba A., Fan S., Dykstra H., McCormick R., et al. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 2012, 32(12):4004-4016.
145. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 2005, 10(5):434-449.
146. Realini N., Rubino T., Parolaro D. Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol. Res. 2009, 60(2):132-138.
147. Rettori E., De Laurentiis A., Zorrilla Zubilete M., Rettori V., Elverdin J.C. Anti-inflammatory effect of the endocannabinoid anandamide in experimental periodontitis and stress in the rat. Neuroimmunomodulation 2012, 19(5):293-303.
148. Ribeiro R., Wen J., Li S., Zhang Y. Involvement of ERK1/2, cPLA2 and NF-kappaB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat. 2013, 100-101:1-14.
149. Robinson R.H., Meissler J.J., Breslow-Deckman J.M., Gaughan J., Adler M.W., Eisenstein T.K. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. J. Neuroimmune Pharmacol. 2013, 8(5):1239-1250.
150. Rock R.B., Gekker G., Hu S., Sheng W.S., Cabral G.A., Martin B.R., et al. WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J. Neuroimmune Pharmacol. 2007, 2(2):178-183.
151. Rockwell C.E., Kaminski N.E. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J. Pharmacol. Exp. Ther. 2004, 311(2):683-690.
152. Rom S., Zuluaga-Ramirez V., Dykstra H., Reichenbach N.L., Pacher P., Persidsky Y. Selective activation of cannabinoid receptor 2 in leukocytes suppresses their engagement of the brain endothelium and protects the blood-brain barrier. Am. J. Pathol. 2013, 183(5):1548-1558.
153. Rossi B., Zenaro E., Angiari S., Ottoboni L., Bach S., Piccio L., et al. Inverse agonism of cannabinoid CB1 receptor blocks the adhesion of encephalitogenic T cells in inflamed brain venules by a protein kinase A-dependent mechanism. J. Neuroimmunol. 2011, 233(1-2):97-105.
154. Roth M.D., Tashkin D.P., Whittaker K.M., Choi R., Baldwin G.C. Tetrahydrocannabinol suppresses immune function and enhances HIV replication in the huPBL-SCID mouse. Life Sci. 2005, 77(14):1711-1722.
155. Sacerdote P., Martucci C., Vaccani A., Bariselli F., Panerai A.E., Colombo A., et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J. Neuroimmunol. 2005, 159(1-2):97-105.
156. Sainz J., Mata I., Barrera J., Perez-Iglesias R., Varela I., Arranz M.J., et al. Inflammatory and immune response genes have significantly altered expression in schizophrenia. Mol. Psychiatry 2013, 18(10):1056-1057.
157. Saunders C.I., Fassett R.G., Geraghty D.P. Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death. Biochim. Biophys. Acta 2009, 1792(10):1019-1026.
158. Schwarz M.J., Muller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med. Hypotheses 2001, 56(4):483-486.
159. Servettaz A., Kavian N., Nicco C., Deveaux V., Chereau C., Wang A., et al. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am. J. Pathol. 2010, 177(1):187-196.
160. Shiratsuchi A., Watanabe I., Yoshida H., Nakanishi Y. Involvement of cannabinoid receptor CB2 in dectin-1-mediated macrophage phagocytosis. Immunol. Cell Biol. 2008, 86(2):179-184.
161. Singh U.P., Singh N.P., Singh B., Price R.L., Nagarkatti M., Nagarkatti P.S. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol. Appl. Pharmacol. 2012, 258(2):256-267.
162. Sisay S., Pryce G., Jackson S.J., Tanner C., Ross R.A., Michael G.J., et al. Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 Receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS ONE 2013, 8(10):e76907.
163. Skaper S.D., Di Marzo V. Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 367(1607):3193-3200.
164. Skaper S.D., Facci L., Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol. 2013, 48(2):340-352.
165. Springs A.E., Karmaus P.W., Crawford R.B., Kaplan B.L., Kaminski N.E. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune compete nce and sensitivity to immune modulation by Delta9-tetrahydrocannabinol. J. Leukoc. Biol. 2008, 84(6):1574-1584.
166. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
167. Steiner J., Mawrin C., Ziegeler A., Bielau H., Ullrich O., Bernstein H.G., et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol. 2006, 112(3):305-316.
168. Stella N. Endocannabinoid signaling in microglial cells. Neuropharmacology 2009, 56(Suppl. 1):244-253.
169. Tanasescu R., Constantinescu C.S. Cannabinoids and the immune system: an overview. Immunobiology 2010, 215(8):588-597.
170. Tanikawa T., Kurohane K., Imai Y. Induction of preferential chemotaxis of unstimulated B-lymphocytes by 2-arachidonoylglycerol in immunized mice. Microbiol. Immunol. 2007, 51(10):1013-1019.
171. Tanikawa T., Kurohane K., Imai Y. Regulatory effect of cannabinoid receptor agonist on chemokine-induced lymphocyte chemotaxis. Biol. Pharm. Bull. 2011, 34(7):1090-1093.
172. Tolon R.M., Nunez E., Pazos M.R., Benito C., Castillo A.I., Martinez-Orgado J.A., et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009, 4(1283):148-154.
173. Torres E., Gutierrez-Lopez M.D., Borcel E., Peraile I., Mayado A., O'Shea E., et al. Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. J. Neurochem. 2010, 113(1):67-78.
174. Torres S., Lorente M., Rodriguez-Fornes F., Hernandez-Tiedra S., Salazar M., Garcia-Taboada E., et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther. 2011, 10(1):90-103.
175. Torrey E.F., Bartko J.J., Yolken R.H. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr. Bull. 2012, 38(3):642-647.
176. Tschop J., Kasten K.R., Nogueiras R., Goetzman H.S., Cave C.M., England L.G., et al. The cannabinoid receptor 2 is critical for the host response to sepsis. J. Immunol. 2009, 183(1):499-505.
177. van Os J., Kapur S. Psychosis: from diagnosis to syndrome. Ned. Tijdschr. Geneeskd. 2010, 154:A1874.
178. van Os J., Krabbendam L., Myin-Germeys I., Delespaul P. The schizophrenia envirome. Curr. Opin. Psychiatry 2005, 18(2):141-145.
179. Vannacci A., Giannini L., Passani M.B., Di Felice A., Pierpaoli S., Zagli G., et al. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. J. Pharmacol. Exp. Ther. 2004, 311(1):256-264.
180. Veen N.D., Selten J.P., van der Tweel I., Feller W.G., Hoek H.W., Kahn R.S. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry 2004, 161(3):501-506.
181. Vicente-Sanchez A., Sanchez-Blazquez P., Rodriguez-Munoz M., Garzon J. HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity. Mol. Brain 2013, 6(1):42.
182. Vuillermot S., Weber L., Feldon J., Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J. Neurosci. 2010, 30(4):1270-1287.
183. Wacnik P.W., Luhr K.M., Hill R.H., Ljunggren H.G., Kristensson K., Svensson M. Cannabinoids affect dendritic cell (DC) potassium channel function and modulate DC T cell stimulatory capacity. J. Immunol. 2008, 181(5):3057-3066.
184. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 2003, 23(4):1398-1405.
185. Wang H., Xu H., Dyck L.E., Li X.M. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 2005, 81(4):572-580.
186. Widmer M., Hanemann C.O., Zajicek J. High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. J. Neurosci. Res. 2008, 86(14):3212-3220.
187. Wilke I., Arolt V., Rothermundt M., Weitzsch C., Hornberg M., Kirchner H. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 1996, 246(5):279-284.
188. Xu H., Cheng C.L., Chen M., Manivannan A., Cabay L., Pertwee R.G., et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J. Leukoc. Biol. 2007, 82(3):532-541.
189. Yamaori S., Ishii H., Chiba K., Yamamoto I., Watanabe K. Delta(8)-tetrahydrocannabinol induces cytotoxicity in macrophage J774-1 cells: Involvement of cannabinoid receptor 2 and p38 MAPK. Toxicology 2013, 314(2-3):254-261.
190. Yang Y., Yang H., Wang Z., Varadaraj K., Kumari S.S., Mergler S., et al. Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-induced inflammatory responses to corneal injury. Cell. Signal. 2013, 25(2):501-511.
191. Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994, 643(1-2):40-49.
192. Zavitsanou K., Dalton V.S., Walker A.K., Weickert C.S., Sominsky L., Hodgson D.M. Neonatal lipopolysaccharide treatment has long-term effects on monoaminergic and cannabinoid receptors in the rat. Synapse 2013, 67(6):290-299.
193. Ziring D., Wei B., Velazquez P., Schrage M., Buckley N.E., Braun J. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 2006, 58(9):714-725.